Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies

1. Disease Information

1.1 Definition and overview

NMOSD with anti‑AQP4 antibodies is an autoimmune inflammatory CNS disorder distinct from multiple sclerosis, unified under the term neuromyelitis optica spectrum disorders (NMOSD) and stratified by AQP4‑IgG serostatus (AQP4‑IgG positive vs negative/unknown). (wingerchuk2015internationalconsensusdiagnostic pages 1-2, wingerchuk2015internationalconsensusdiagnostic pages 3-3)

Core concept: In AQP4‑IgG+ disease, pathogenic antibodies target the astrocyte water channel aquaporin‑4 (AQP4), producing an astrocytopathy with secondary demyelination and neuroaxonal injury. (contentti2021neuromyelitisopticaspectrum pages 1-2, collongues2019pharmacotherapyforneuromyelitis pages 1-2)

1.2 Key identifiers and controlled vocabularies

• MONDO / Orphanet / ICD-10/ICD-11 / MeSH: Not retrieved in the current evidence set; recommended to populate from MONDO/Orphanet/WHO ICD browsers and MeSH “Neuromyelitis Optica” entries. (Gap)

1.3 Synonyms and alternative names

• Neuromyelitis optica (NMO)
• Devic disease (historical)
• AQP4‑IgG‑positive NMOSD / AQP4‑Ab+ NMOSD (wingerchuk2015internationalconsensusdiagnostic pages 3-3, wingerchuk2015internationalconsensusdiagnostic pages 5-6)

1.4 Diagnostic category per 2015 IPND

The 2015 International Panel for NMO Diagnosis (IPND) created two categories: 1) NMOSD with AQP4‑IgG 2) NMOSD without AQP4‑IgG (or unknown) (wingerchuk2015internationalconsensusdiagnostic pages 3-3, bennett2016findingnmothe pages 11-12)

Visual evidence: the IPND criteria table is available as a cropped image from the original consensus paper. (wingerchuk2015internationalconsensusdiagnostic media 83817c93)

2. Etiology

2.1 Primary causal factors

Autoantibody-mediated astrocytopathy: AQP4‑IgG binds AQP4 at astrocyte endfeet, triggers classical complement activation and inflammatory injury; astrocyte loss precedes secondary demyelination/neuronal injury. (contentti2021neuromyelitisopticaspectrum pages 1-2, collongues2019pharmacotherapyforneuromyelitis pages 1-2)

2.2 Risk factors

Sex: Strong female predominance is consistent across cohorts and meta-analysis (female:male ~8.9 overall). (arnett2024sexratioand pages 1-2, sechi2024epidemiologyofaquaporin4iggpositive pages 8-12)

Coexisting autoimmunity: Coexisting systemic autoimmune diseases are common; in Sardinia 52% had concomitant autoimmune disorders (autoimmune thyroiditis most frequent). (sechi2024epidemiologyofaquaporin4iggpositive pages 8-12, sechi2024epidemiologyofaquaporin4iggpositive pages 34-37)

Environmental factors (suggested): Proposed factors include infections, smoking, and vitamin D deficiency, based on epidemiologic discussion; high-quality causal estimates were not identified in the current evidence set. (sechi2024epidemiologyofaquaporin4iggpositive pages 34-37)

2.3 Genetic susceptibility (non-Mendelian)

No single causal gene defines AQP4‑IgG+ NMOSD. Reported susceptibility loci/haplotypes include HLA‑DPB1, HLA‑DRB1*03:01, immune regulatory variants (e.g., PTPN22 PD‑1.3A allele, CD226 Gly307Ser) and possible protective signal at CYP7A1 G/G; HLA‑DRB1*1501 (MS risk) is not associated with NMO. (melamed2015updateonbiomarkers pages 4-5, contentti2021neuromyelitisopticaspectrum pages 2-4)

2.4 Protective factors and gene–environment interactions

No robust protective factors or formal gene–environment interaction studies were retrieved in the current evidence set. (Gap)

3. Phenotypes

3.1 Core clinical characteristics (2015 IPND)

For AQP4‑IgG+ NMOSD, ≥1 of the following core clinical characteristics is sufficient (with AQP4‑IgG positivity and exclusion of alternative diagnoses): 1) Optic neuritis 2) Acute myelitis 3) Area postrema syndrome (hiccups or nausea/vomiting) 4) Acute brainstem syndrome 5) Diencephalic syndrome (e.g., symptomatic narcolepsy) with typical features 6) Symptomatic cerebral syndrome with NMOSD-typical lesions (wingerchuk2015internationalconsensusdiagnostic pages 3-3, bennett2016findingnmothe pages 11-12)

3.2 Frequency and presentation statistics

AQP4‑IgG+ cohort phenotype frequencies (Korea cohort evaluating 2015 criteria): * Acute myelitis occurred in 190/226 (84%) (disease course) (hyun2016evaluationofthe pages 4-6) * Symptomatic brain syndromes occurred in 100/252 (40%) overall, with lesion-category counts area postrema 16%, brainstem 16%, cerebral 15% (hyun2016evaluationofthe pages 4-6)

Sardinia incident AQP4‑IgG+ cases (2013–2022): * LETM 68% * Optic neuritis 16% * Brainstem syndromes 6% * Encephalitis 3% * Combinations 6% (including area postrema syndromes) (sechi2024epidemiologyofaquaporin4iggpositive pages 8-12)

3.3 Temporal patterns (onset and course)

NMOSD is generally relapsing: 80–90% relapsing course; after first attack 60% relapse within 1 year and 90% within 3 years (older but widely cited synthesis). (jasiakzatonska2016theimmunologyof pages 3-6)

3.4 Quality of life (QoL)

QoL and fatigue are recognized as burdensome symptoms in NMOSD, but disease‑specific quantitative QoL metrics and 2023–2024 trial‑embedded QoL data were not retrieved in the current evidence set. (duchow2020currentandemerging pages 1-5)

3.5 Suggested HPO terms (examples)

• Optic neuritis – HP:0000540
• Transverse myelitis – HP:0002240
• Nausea – HP:0002018; Vomiting – HP:0002013; Hiccups – HP:0002030 (area postrema syndrome features)
• Paraplegia – HP:0003401
• Blindness – HP:0000618 (These ontology mappings are suggested; not validated in retrieved texts.)

4. Genetic / Molecular Information

4.1 Causal genes

NMOSD with AQP4‑IgG is not a monogenic disorder; AQP4 is the antigenic target, not typically mutated. (contentti2021neuromyelitisopticaspectrum pages 1-2)

4.2 AQP4 protein biology relevant to pathogenesis

AQP4 is enriched at astrocyte endfeet and forms supramolecular orthogonal arrays of particles (OAPs), with M23 favoring OAPs; OAP clustering facilitates complement activation after antibody binding. (chan2021treatmentofneuromyelitis pages 2-3, contentti2021neuromyelitisopticaspectrum pages 2-4)

4.3 Biomarkers and targets

• AQP4‑IgG (serum) is the key diagnostic biomarker; CSF-only positivity is rare. (wingerchuk2015internationalconsensusdiagnostic pages 5-6, contentti2021neuromyelitisopticaspectrum pages 2-4)
• GFAP is discussed as an emerging biomarker concept in the biomarker literature; prospective validation was not available in the retrieved primary dataset. (bennett2016findingnmothe pages 3-4)
• Therapeutic targets with approval-stage evidence include IL6R, CD19, C5 (OpenTargets). (OpenTargets Search: Neuromyelitis optica spectrum disorder)

4.4 Epigenetics and omics

No robust epigenetic or multi‑omics (transcriptomic/proteomic/metabolomic) signatures were retrieved in the current evidence set. (Gap)

5. Mechanism / Pathophysiology

5.1 Causal chain (current understanding)

1) Peripheral immune dysregulation with plasmablast expansion; IL‑6 supports plasmablast survival and AQP4‑Ab secretion. (contentti2021neuromyelitisopticaspectrum pages 2-4) 2) AQP4‑IgG enters CNS via disrupted BBB or permissive regions and binds AQP4 on astrocyte endfeet/ependymal surfaces. (contentti2021neuromyelitisopticaspectrum pages 2-4) 3) Binding triggers classical complement activation and inflammatory infiltration (neutrophils/eosinophils/macrophages), causing astrocyte injury with loss of AQP4 and GFAP, then secondary demyelination and neuronal injury. (collongues2019pharmacotherapyforneuromyelitis pages 1-2, contentti2021neuromyelitisopticaspectrum pages 1-2)

5.2 2024 mechanistic developments

Complement-dependent Th17 cytokine release: PBMCs from treatment‑naïve AQP4‑IgG+ NMOSD patients stimulated with AQP4 immune complexes + complement produced elevated IL‑17A and IL‑6, supporting a complement‑dependent Th17‑biased peripheral inflammatory loop. (Feb 2024; https://doi.org/10.1038/s41598-024-53661-5) (nishiyama2024antiaquaporin4immunecomplex pages 1-2)

IFN‑γ axis and modeling: Decreased IFN‑γ receptor signaling and IFN‑γ depletion in AQP4 peptide‑immunized mice produced severe NMOSD‑like disease; IL‑6/Th17 activation increased, and targeting IL‑17A, IL‑6R, or B cells improved disease; a tolerance strategy (AQP4‑peptide PLGA nanoparticles) prevented/treated disease in the model. (Nov 2024; https://doi.org/10.1093/brain/awad373) (arellano2024interferonγcontrolsaquaporin4specific pages 1-2)

5.3 Suggested GO biological processes / cell types (examples)

• GO:0006956 complement activation
• GO:0006955 immune response
• GO:0006954 inflammatory response
• GO:0006957 complement activation, classical pathway
• CL:0000127 astrocyte; CL:0000540 microglial cell; CL:0000775 neutrophil; CL:0000236 B cell; CL:0000624 CD4-positive T cell (These are suggested mappings; not explicitly enumerated in the retrieved texts.)

6. Anatomical Structures Affected

6.1 Organ/system level

Primarily affects the central nervous system with lesions in: * Optic nerve/chiasm (optic neuritis) (wingerchuk2015internationalconsensusdiagnostic pages 5-6) * Spinal cord (LETM; central cord predilection) (wingerchuk2015internationalconsensusdiagnostic pages 5-6) * Dorsal medulla/area postrema (area postrema syndrome) (wingerchuk2015internationalconsensusdiagnostic pages 5-6) * Periependymal regions around the third/fourth ventricles, hypothalamus/thalamus (wingerchuk2015internationalconsensusdiagnostic pages 5-6)

6.2 Tissue/cell level

Targeted cell compartment: astrocyte endfeet at the BBB and ependymal surfaces, reflecting AQP4 localization. (collongues2019pharmacotherapyforneuromyelitis pages 1-2, contentti2021neuromyelitisopticaspectrum pages 2-4)

6.3 Subcellular level

AQP4 supramolecular organization into OAPs influences complement activation, linking membrane organization to cytotoxicity. (chan2021treatmentofneuromyelitis pages 2-3, jasiakzatonska2016theimmunologyof pages 8-10)

7. Temporal Development

• Onset: Typically adult onset; in Sardinia median onset 54 years with rare pediatric onset. (sechi2024epidemiologyofaquaporin4iggpositive pages 8-12)
• Course: Relapses drive disability; gradual progression is rare (red flag). (wingerchuk2015internationalconsensusdiagnostic pages 3-4)

8. Inheritance and Population

8.1 Epidemiology (recent quantitative estimates)

• Population-based Sardinia study (May 2024): incidence 1.9 per million person‑years and prevalence 2.6 per 100,000 (AQP4‑IgG+ NMOSD). (sechi2024epidemiologyofaquaporin4iggpositive pages 8-12)
• Reviews summarize broad prevalence ranges and highlight ancestry differences (higher in East‑Asian and African‑Caribbean populations). (duchow2020currentandemerging pages 1-5, sechi2024epidemiologyofaquaporin4iggpositive pages 12-14)

8.2 Sex ratio and age of onset

Meta-analysis estimate for AQP4‑IgG+ NMOSD: female:male 8.89 (95% CI 7.78–10.15); pediatric estimate 5.68; late-onset 5.48. (Jul 2024; https://doi.org/10.1007/s00415-024-12452-8) (arnett2024sexratioand pages 1-2)

8.3 Inheritance

No Mendelian inheritance pattern is established; susceptibility appears polygenic/immune‑regulatory. (melamed2015updateonbiomarkers pages 4-5)

9. Diagnostics

9.1 Clinical criteria (2015 IPND)

For AQP4‑IgG+ NMOSD diagnosis requires: 1) At least one core clinical characteristic, 2) Positive AQP4‑IgG (best available method; CBA strongly recommended), 3) Exclusion of alternative diagnoses. (wingerchuk2015internationalconsensusdiagnostic pages 3-3, bennett2016findingnmothe pages 11-12)

9.2 AQP4‑IgG testing and performance

2015 IPND emphasizes cell‑based serum assays (microscopy/flow) as preferred, citing pooled mean sensitivity ~76.7% and very low false-positive rate (~0.1% in an MS clinic cohort), while ELISA and IIF have lower sensitivity and more false positives. (wingerchuk2015internationalconsensusdiagnostic pages 5-6)

A separate review summarizes assay performance across platforms (example: CBA ~91% sensitivity/100% specificity reported in that review). (jasiakzatonska2016theimmunologyof pages 11-14)

9.3 MRI and CSF patterns

• Spinal MRI: LETM (≥3 vertebral segments), central gray matter predilection. (wingerchuk2015internationalconsensusdiagnostic pages 4-5)
• Optic nerve MRI: long lesions, posterior/chiasm involvement. (wingerchuk2015internationalconsensusdiagnostic pages 4-5)
• Brain MRI: dorsal medulla/area postrema; periependymal third/fourth ventricle lesions; hypothalamus/thalamus; long corticospinal/corpus callosum lesions. (wingerchuk2015internationalconsensusdiagnostic pages 5-6)
• CSF (typical): pleocytosis often >50 cells/mm³, neutrophils; elevated protein (100–500 mg/dL); oligoclonal bands uncommon (~15–30%). (jasiakzatonska2016theimmunologyof pages 3-6)

9.4 Differential diagnosis

Red flags favoring MS include Dawson fingers/cortical lesions, typical MS brain lesion distribution, and high frequency of oligoclonal bands; MOG‑IgG should be tested in seronegative NMOSD phenotypes. (wingerchuk2015internationalconsensusdiagnostic pages 5-6, seze2016neuromyelitisopticaspectrum pages 1-2)

9.5 Suggested LOINC-like test concepts (examples)

• Serum aquaporin‑4 IgG by cell-based immunoassay (preferred)
• CSF oligoclonal bands
• CSF cell count and differential (Actual LOINC codes not retrieved.)

10. Outcome / Prognosis

10.1 Relapse-driven disability

Relapses are the main driver of irreversible disability; severe relapses can cause blindness and paralysis. (contentti2021neuromyelitisopticaspectrum pages 2-4)

10.2 Relapse probability and prognostic factors

Older synthesis: after first attack 60% relapse within 1 year and 90% within 3 years; worse prognosis linked to high early relapse frequency, severe first attack, and coexisting systemic autoimmunity. (jasiakzatonska2016theimmunologyof pages 3-6)

Pediatric AQP4‑IgG+ NMOSD: non‑White ethnicity associated with shorter time to first relapse and worse EDSS at last follow‑up. (paolilo2020treatmentandoutcome pages 3-4)

10.3 Modern outcomes with targeted therapy

Real-world eculizumab cohort (Germany/Austria, 2014–2022): 88% attack-free; median annualized attack rate decreased from 1.0 to 0; EDSS stable (median 6.0). (ringelstein2024eculizumabusein pages 1-2)

11. Treatment

11.1 Acute relapse treatment

• High-dose IV methylprednisolone is standard initial therapy; plasma exchange (PLEX) is used for refractory attacks. (contentti2021neuromyelitisopticaspectrum pages 2-4, tugizova2021newtherapeuticlandscape pages 1-4)

11.2 Relapse prevention: pivotal trials (key statistics)

• Eculizumab (C5 inhibitor; PREVENT RCT, NEJM 2019): relapses 3/96 (3%) vs 20/47 (43%); HR 0.06 (95% CI 0.02–0.20; p<0.001); trial ARR 0.02 vs 0.35. (Aug 2019; https://doi.org/10.1056/NEJMoa1900866) (pittock2019eculizumabinaquaporin4–positive pages 1-2)
• Satralizumab (IL‑6R inhibitor):
• Add-on SAkuraSky (NEJM 2019): relapse 20% vs 43% overall; AQP4‑IgG+ subgroup relapse 11% vs 43%; HRs provided in secondary synthesis. (contentti2021neuromyelitisopticaspectrum pages 11-13)
• Monotherapy SAkuraStar (Lancet Neurol 2020): relapse 30% vs 50%; HR 0.45 (95% CI 0.23–0.89; p=0.018). (May 2020; https://doi.org/10.1016/S1474-4422(20)30078-8) (traboulsee2020safetyandefficacy pages 1-2)
• Inebilizumab (anti‑CD19; N‑MOmentum): relapse 12% (21/174) vs 39% (22/56); AQP4+ relapse 11% (18/161) vs 42% (22/52); disability benefit reported (3‑month CDP HR 0.375). (tugizova2021newtherapeuticlandscape pages 9-11)

11.3 Real-world implementation and safety considerations (2024)

Eculizumab real-world cohort: vaccination prior to therapy was common; 19% had attacks shortly after pre‑treatment meningococcal vaccination when not on prednisone; serious infections in 13% and deaths in 10% (including meningococcal sepsis). (ringelstein2024eculizumabusein pages 1-2)

11.4 Ravulizumab (2024 update)

Ravulizumab achieved immediate and sustained terminal complement inhibition in CHAMPION‑NMOSD pharmacology analyses; indirect comparisons suggest strong relapse prevention versus other mechanisms. (clardy2024networkmetaanalysisof pages 1-3)

11.5 Suggested MAXO terms (examples)

• Plasma exchange therapy – MAXO:0000503 (suggested)
• High‑dose corticosteroid therapy – MAXO term needed (suggested)
• Monoclonal antibody therapy – MAXO:0000142 (suggested) (Exact MAXO IDs not retrieved.)

12. Prevention

12.1 Primary prevention

No established strategy prevents initial development of AQP4‑IgG autoimmunity. (Gap)

12.2 Secondary prevention

Early recognition using IPND criteria and high‑specificity AQP4‑IgG testing enables earlier disease-modifying therapy and avoidance of MS therapies that may worsen NMOSD. (wingerchuk2015internationalconsensusdiagnostic pages 3-3, bennett2016findingnmothe pages 3-4)

12.3 Tertiary prevention

Maintenance immunotherapy to prevent relapses is the central prevention strategy; complement inhibitor use requires meningococcal vaccination and careful infection vigilance. (chan2021treatmentofneuromyelitis pages 17-19, ringelstein2024eculizumabusein pages 1-2)

13. Other Species / Natural Disease

Naturally occurring AQP4‑IgG NMOSD in non‑human species was not identified in the current evidence set. (Gap)

14. Model Organisms

14.1 Passive-transfer and experimental lesion models

AQP4‑IgG + complement applied to in vitro/ex vivo CNS tissues or injected into CNS regions produces NMO‑like lesions (AQP4 loss, astrocytopathy, demyelination, neuron loss) but often requires BBB disruption or local delivery, limiting modeling of chronic relapsing disease. (xu2025aquaporin4iggseropositiveneuromyelitisoptica pages 4-5, xu2025aquaporin4iggseropositiveneuromyelitisoptica pages 8-8)

14.2 2024 AQP4 peptide immunization model (IFN‑γ depletion)

IFN‑γ depletion in AQP4_201–220‑immunized mice induces severe NMOSD‑like disease and provides a platform to test IL‑17A/IL‑6R/B‑cell targeting and tolerization nanoparticles. (arellano2024interferonγcontrolsaquaporin4specific pages 1-2)

14.3 2024 humanized-AQP4 rat model

Gene‑edited rats expressing humanized AQP4 extracellular domains enable astrocyte‑loss lesions to be induced by human AQP4‑specific antibodies, addressing species-binding limitations. (Jul 2024; https://doi.org/10.3390/ijms25158169) (namatame2024humanizedaquaporin4expressingratcreated pages 1-2)

Current applications and real-world implementations

• Clinical application of IPND criteria with cell‑based AQP4‑IgG assays enables diagnosis after a single core clinical event in seropositive patients, influencing earlier initiation of relapse-prevention therapy. (wingerchuk2015internationalconsensusdiagnostic pages 3-3, wingerchuk2015internationalconsensusdiagnostic pages 5-6)
• Relapse prevention now uses mechanism‑targeted biologics (C5 inhibition, IL‑6R blockade, CD19 B‑cell depletion) with demonstrated RCT efficacy and expanding real‑world safety datasets. (pittock2019eculizumabinaquaporin4–positive pages 1-2, traboulsee2020safetyandefficacy pages 1-2, ringelstein2024eculizumabusein pages 1-2)

Expert opinions and authoritative analyses

• The IPND emphasizes that seropositive NMOSD can present with diverse neuroanatomic syndromes, and that cell‑based assays should be used due to sensitivity/specificity advantages. (wingerchuk2015internationalconsensusdiagnostic pages 5-6, wingerchuk2015internationalconsensusdiagnostic pages 3-3)
• Reviews in high-impact neurology journals frame relapse prevention as the key therapeutic goal because disability accrues from attacks rather than progressive degeneration. (contentti2021neuromyelitisopticaspectrum pages 2-4, levy2021newtherapiesfor pages 3-4)

Embedded evidence summary table

Table: This table summarizes the defining 2015 diagnostic criteria for AQP4-IgG-positive NMOSD and the major relapse-prevention therapies with pivotal trial outcomes, plus key 2024 clinical updates. It is useful as a compact reference for diagnosis and current treatment evidence.

Notable evidence gaps (for knowledge-base completion)

• Ontology identifiers (MONDO, ICD-10/11, Orphanet, MeSH) were not retrievable from the current tool context and should be filled via dedicated ontology lookups.
• Robust 2023–2024 QoL metrics, OCT retinal thickness meta-analytic values, and multi‑omics/epigenetic datasets were not captured in the evidence retrieved here.

References

1. (wingerchuk2015internationalconsensusdiagnostic pages 3-3): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5364 citations and is from a highest quality peer-reviewed journal.

2. (pittock2019eculizumabinaquaporin4–positive pages 1-2): Sean J. Pittock, Achim Berthele, Kazuo Fujihara, Ho Jin Kim, Michael Levy, Jacqueline Palace, Ichiro Nakashima, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, Kai-Chen Wang, Amy Pace, Kenji P. Fujita, Róisín Armstrong, and Dean M. Wingerchuk. Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. New England Journal of Medicine, 381:614-625, Aug 2019. URL: https://doi.org/10.1056/nejmoa1900866, doi:10.1056/nejmoa1900866. This article has 957 citations and is from a highest quality peer-reviewed journal.

3. (ringelstein2024eculizumabusein pages 1-2): Marius Ringelstein, Susanna Asseyer, Gero Lindenblatt, Katinka Fischer, Refik Pul, Jelena Skuljec, Lisa Revie, Katrin Giglhuber, Vivien Häußler, Michael Karenfort, Kerstin Hellwig, Friedemann Paul, Judith Bellmann-Strobl, Carolin Otto, Klemens Ruprecht, Tjalf Ziemssen, Alexander Emmer, Veit Rothhammer, Florian T. Nickel, Klemens Angstwurm, Ralf Linker, Sarah A. Laurent, Clemens Warnke, Sven Jarius, Mirjam Korporal-Kuhnke, Brigitte Wildemann, Stephanie Wolff, Maria Seipelt, Yavor Yalachkov, Nele Retzlaff, Uwe K. Zettl, Paulus S. Rommer, Markus C. Kowarik, Jonathan Wickel, Christian Geis, Martin W. Hümmert, Corinna Trebst, Makbule Senel, Ralf Gold, Luisa Klotz, Christoph Kleinschnitz, Sven G. Meuth, Orhan Aktas, Achim Berthele, and Ilya Ayzenberg. Eculizumab use in neuromyelitis optica spectrum disorders. Neurology, Nov 2024. URL: https://doi.org/10.1212/wnl.0000000000209888, doi:10.1212/wnl.0000000000209888. This article has 32 citations and is from a highest quality peer-reviewed journal.

4. (sechi2024epidemiologyofaquaporin4iggpositive pages 8-12): Elia Sechi, Mariangela Puci, Maria Ida Pateri, Pietro Zara, Sabrine Othmani, Stefano Sotgiu, Maria Valeria Saddi, Stefania Leoni, Giuseppe Fenu, Maurizio Melis, Giovanni Sotgiu, Paolo Solla, Eleonora Cocco, and Jessica Frau. Epidemiology of aquaporin-4-igg-positive nmosd in sardinia. Multiple Sclerosis and Related Disorders, 85:105522, May 2024. URL: https://doi.org/10.1016/j.msard.2024.105522, doi:10.1016/j.msard.2024.105522. This article has 4 citations and is from a peer-reviewed journal.

5. (arnett2024sexratioand pages 1-2): Simon Arnett, Sin Hong Chew, Unnah Leitner, Jyh Yung Hor, Friedemann Paul, Michael R. Yeaman, Michael Levy, Brian G. Weinshenker, Brenda L. Banwell, Kazuo Fujihara, Hesham Abboud, Irena Dujmovic Basuroski, Georgina Arrambide, Veronika E. Neubrand, Chao Quan, Esther Melamed, Jacqueline Palace, Jing Sun, Nasrin Asgari, Simon A. Broadley, Hesham Abboud, Orhan Aktas, Raed Alroughani, Ayse Altintas, Metha Apiwattannakul, Georgina Arrambide, Jagannadha Avasarala, Brenda Banwell, Terrence F. Blaschke, James Bowen, Edgar Carnero Contentti, Tanuja Chitnis, Jerome de Seze, Guillermo Delgado-Garcia, Irena Dujmovic Basuroski, Jose Flores, Kazuo Fujihara, Lorna Galleguillos, Benjamin M. Greenberg, May Han, Joachim Havla, Kerstin Hellwig, Jyh Yung Hor, Sven Jarius, Jorge Andres Jimenez, Najib Kissani, Ingo Kleiter, Marco Lana-Peixoto, M. Isabel Leite, Michael Levy, Sara Mariotto, Maureen A. Mealy, Veronika E. Neubrand, Celia Oreja-Guevara, Lekha Pandit, Sarah M. Planchon, Anne-Katrin Pröbstel, Peiqing Qian, Chao Quan, Pavle Repovic, Claire Riley, Marius Ringelstein, Juan I.Rojas, Dalia Rotstein, Klemens Ruprecht, Maria José Sá, Albert Saiz, Sara Salama, Sasitorn Siritho, Aksel Siva, Terry J. Smith, Elias S. Sotirchos, Ibis Soto de Castillo, Silvia Tenembaum, Pablo Villoslada, Barbara Willekens, Dean Wingerchuk, Bassem I. Yamout, and Michael Yeaman. Sex ratio and age of onset in aqp4 antibody-associated nmosd: a review and meta-analysis. Journal of Neurology, 271:4794-4812, Jul 2024. URL: https://doi.org/10.1007/s00415-024-12452-8, doi:10.1007/s00415-024-12452-8. This article has 39 citations and is from a domain leading peer-reviewed journal.

6. (nishiyama2024antiaquaporin4immunecomplex pages 1-2): Shuhei Nishiyama, Jin Myong Seok, Amy E. Wright, Itay Lotan, Takahisa Mikami, Natalia C. Drosu, Natasha Bobrowski-Khoury, Monique R. Anderson, Philippe A. Bilodeau, Patrick Schindler, Friedemann Paul, Masashi Aoki, Michael R. Yeaman, Michael Levy, Jacinta M. Behne, Megan K. Behne, Jeffrey L. Bennett, Terrence F. Blaschke, Tanuja Chitnis, Lawrence J. Cook, Michael Levy, Sarah M. Planchon, Pavle Repovic, Claire S. Riley, Terry J. Smith, Anthony Traboulsee, and Michael R. Yeaman. Anti-aquaporin-4 immune complex stimulates complement-dependent th17 cytokine release in neuromyelitis optica spectrum disorders. Scientific Reports, Feb 2024. URL: https://doi.org/10.1038/s41598-024-53661-5, doi:10.1038/s41598-024-53661-5. This article has 20 citations and is from a peer-reviewed journal.

7. (arellano2024interferonγcontrolsaquaporin4specific pages 1-2): Gabriel Arellano, Eileah Loda, Yanan Chen, Tobias Neef, Andrew C Cogswell, Grant Primer, Godwin Joy, Kevin Kaschke, Samantha Wills, Joseph R Podojil, Brian Popko, Roumen Balabanov, and Stephen D Miller. Interferon-γ controls aquaporin-4-specific th17 and b cells in neuromyelitis optica spectrum disorder. Brain : a journal of neurology, 147:1344-1361, Nov 2024. URL: https://doi.org/10.1093/brain/awad373, doi:10.1093/brain/awad373. This article has 26 citations.

8. (clardy2024networkmetaanalysisof pages 1-3): Stacey L. Clardy, Sean J. Pittock, Orhan Aktas, Jin Nakahara, Noriko Isobe, Diego Centonze, Sami Fam, Adrian Kielhorn, Jeffrey C. Yu, Jeroen Jansen, and Ina Zhang. Network meta-analysis of ravulizumab and alternative interventions for the treatment of neuromyelitis optica spectrum disorder. Neurology and Therapy, 13:535-549, May 2024. URL: https://doi.org/10.1007/s40120-024-00597-7, doi:10.1007/s40120-024-00597-7. This article has 24 citations and is from a domain leading peer-reviewed journal.

9. (wingerchuk2015internationalconsensusdiagnostic pages 1-2): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5364 citations and is from a highest quality peer-reviewed journal.

10. (contentti2021neuromyelitisopticaspectrum pages 1-2): Edgar Carnero Contentti and Jorge Correale. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. Journal of Neuroinflammation, Sep 2021. URL: https://doi.org/10.1186/s12974-021-02249-1, doi:10.1186/s12974-021-02249-1. This article has 376 citations and is from a peer-reviewed journal.

11. (collongues2019pharmacotherapyforneuromyelitis pages 1-2): Nicolas Collongues, Estelle Ayme-Dietrich, Laurent Monassier, and Jérôme de Seze. Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options. Drugs, 79:125-142, Jan 2019. URL: https://doi.org/10.1007/s40265-018-1039-7, doi:10.1007/s40265-018-1039-7. This article has 73 citations and is from a domain leading peer-reviewed journal.

12. (wingerchuk2015internationalconsensusdiagnostic pages 5-6): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5364 citations and is from a highest quality peer-reviewed journal.

13. (bennett2016findingnmothe pages 11-12): Jeffrey L. Bennett. Finding nmo: the evolving diagnostic criteria of neuromyelitis optica. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 36 3:238-45, Sep 2016. URL: https://doi.org/10.1097/wno.0000000000000396, doi:10.1097/wno.0000000000000396. This article has 57 citations.

14. (wingerchuk2015internationalconsensusdiagnostic media 83817c93): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5364 citations and is from a highest quality peer-reviewed journal.

15. (sechi2024epidemiologyofaquaporin4iggpositive pages 34-37): Elia Sechi, Mariangela Puci, Maria Ida Pateri, Pietro Zara, Sabrine Othmani, Stefano Sotgiu, Maria Valeria Saddi, Stefania Leoni, Giuseppe Fenu, Maurizio Melis, Giovanni Sotgiu, Paolo Solla, Eleonora Cocco, and Jessica Frau. Epidemiology of aquaporin-4-igg-positive nmosd in sardinia. Multiple Sclerosis and Related Disorders, 85:105522, May 2024. URL: https://doi.org/10.1016/j.msard.2024.105522, doi:10.1016/j.msard.2024.105522. This article has 4 citations and is from a peer-reviewed journal.

16. (melamed2015updateonbiomarkers pages 4-5): Esther Melamed, Michael Levy, Patrick J. Waters, Douglas Kazutoshi Sato, Jeffrey L. Bennett, Gareth R. John, Douglas C. Hooper, Albert Saiz, Amit Bar-Or, Ho Jin Kim, Lakha Pandit, Maria Isabel Leite, Nasrin Asgari, Najib Kissani, Rogier Hintzen, Romain Marignier, Sven Jarius, John Marcelletti, Terry J. Smith, Michael R. Yeaman, May H. Han, Orhan Aktas, Metha Apiwattanakul, Brenda Banwell, Denis Bichuetti, Simon Broadley, Philippe Cabre, Tanuja Chitnis, Jerome De Seze, Kazuo Fujihara, Benjamin Greenberg, Kerstin Hellwig, Raffaele Iorio, Sven Jarius, Eric Klawiter, Ingo Kleiter, Marco Lana-Peixoto, Nakashima, Kevin O'Connor, Jacqueline Palace, Friedman Paul, Naraporn Prayoonwiwat, Klemens Ruprecht, Olaf Stuve, Thomas Tedder, Silvia Tenembaum, Juan P. Garrahan, Buenos Aires, Katja van Herle, Danielle van Pelt, Pablo Villoslada, Emmanuelle Waubant, Brian Weinshenker, Dean Wingerchuk, Jens Würfel, and Scott Zamvil. Update on biomarkers in neuromyelitis optica. Neurology Neuroimmunology & Neuroinflammation, Aug 2015. URL: https://doi.org/10.1212/nxi.0000000000000134, doi:10.1212/nxi.0000000000000134. This article has 146 citations.

17. (contentti2021neuromyelitisopticaspectrum pages 2-4): Edgar Carnero Contentti and Jorge Correale. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. Journal of Neuroinflammation, Sep 2021. URL: https://doi.org/10.1186/s12974-021-02249-1, doi:10.1186/s12974-021-02249-1. This article has 376 citations and is from a peer-reviewed journal.

18. (hyun2016evaluationofthe pages 4-6): Jae-Won Hyun, In Hye Jeong, AeRan Joung, Su-Hyun Kim, and Ho Jin Kim. Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. Neurology, 86:1772-1779, May 2016. URL: https://doi.org/10.1212/wnl.0000000000002655, doi:10.1212/wnl.0000000000002655. This article has 99 citations and is from a highest quality peer-reviewed journal.

19. (jasiakzatonska2016theimmunologyof pages 3-6): Michalina Jasiak-Zatonska, Alicja Kalinowska-Lyszczarz, Slawomir Michalak, and Wojciech Kozubski. The immunology of neuromyelitis optica—current knowledge, clinical implications, controversies and future perspectives. International Journal of Molecular Sciences, 17:273, Mar 2016. URL: https://doi.org/10.3390/ijms17030273, doi:10.3390/ijms17030273. This article has 148 citations.

20. (duchow2020currentandemerging pages 1-5): Ankelien Duchow, Friedemann Paul, and Judith Bellmann-Strobl. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. Expert Opinion on Biological Therapy, 20:1061-1072, Apr 2020. URL: https://doi.org/10.1080/14712598.2020.1749259, doi:10.1080/14712598.2020.1749259. This article has 25 citations and is from a peer-reviewed journal.

21. (chan2021treatmentofneuromyelitis pages 2-3): Koon-Ho Chan and Chi-Yan Lee. Treatment of neuromyelitis optica spectrum disorders. International Journal of Molecular Sciences, 22:8638, Aug 2021. URL: https://doi.org/10.3390/ijms22168638, doi:10.3390/ijms22168638. This article has 74 citations.

22. (bennett2016findingnmothe pages 3-4): Jeffrey L. Bennett. Finding nmo: the evolving diagnostic criteria of neuromyelitis optica. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 36 3:238-45, Sep 2016. URL: https://doi.org/10.1097/wno.0000000000000396, doi:10.1097/wno.0000000000000396. This article has 57 citations.

23. (OpenTargets Search: Neuromyelitis optica spectrum disorder): Open Targets Query (Neuromyelitis optica spectrum disorder, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

24. (jasiakzatonska2016theimmunologyof pages 8-10): Michalina Jasiak-Zatonska, Alicja Kalinowska-Lyszczarz, Slawomir Michalak, and Wojciech Kozubski. The immunology of neuromyelitis optica—current knowledge, clinical implications, controversies and future perspectives. International Journal of Molecular Sciences, 17:273, Mar 2016. URL: https://doi.org/10.3390/ijms17030273, doi:10.3390/ijms17030273. This article has 148 citations.

25. (wingerchuk2015internationalconsensusdiagnostic pages 3-4): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5364 citations and is from a highest quality peer-reviewed journal.

26. (sechi2024epidemiologyofaquaporin4iggpositive pages 12-14): Elia Sechi, Mariangela Puci, Maria Ida Pateri, Pietro Zara, Sabrine Othmani, Stefano Sotgiu, Maria Valeria Saddi, Stefania Leoni, Giuseppe Fenu, Maurizio Melis, Giovanni Sotgiu, Paolo Solla, Eleonora Cocco, and Jessica Frau. Epidemiology of aquaporin-4-igg-positive nmosd in sardinia. Multiple Sclerosis and Related Disorders, 85:105522, May 2024. URL: https://doi.org/10.1016/j.msard.2024.105522, doi:10.1016/j.msard.2024.105522. This article has 4 citations and is from a peer-reviewed journal.

27. (jasiakzatonska2016theimmunologyof pages 11-14): Michalina Jasiak-Zatonska, Alicja Kalinowska-Lyszczarz, Slawomir Michalak, and Wojciech Kozubski. The immunology of neuromyelitis optica—current knowledge, clinical implications, controversies and future perspectives. International Journal of Molecular Sciences, 17:273, Mar 2016. URL: https://doi.org/10.3390/ijms17030273, doi:10.3390/ijms17030273. This article has 148 citations.

28. (wingerchuk2015internationalconsensusdiagnostic pages 4-5): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5364 citations and is from a highest quality peer-reviewed journal.

29. (seze2016neuromyelitisopticaspectrum pages 1-2): J. D. Seze, L. Kremer, and N. Collongues. Neuromyelitis optica spectrum disorder (nmosd): a new concept. Revue neurologique, 172 4-5:256-62, Apr 2016. URL: https://doi.org/10.1016/j.neurol.2016.03.003, doi:10.1016/j.neurol.2016.03.003. This article has 60 citations and is from a peer-reviewed journal.

30. (paolilo2020treatmentandoutcome pages 3-4): Renata Barbosa Paolilo, Yael Hacohen, Elise Yazbeck, Thais Armangue, Arlette Bruijstens, Christian Lechner, Samira Luisa Apostolos-Pereira, Yana Martynenko, Markus Breu, Carolina de Medeiros Rimkus, Evangeline Wassmer, Matthias Baumann, Laura Papetti, Marco Capobianco, Barbara Kornek, Kevin Rostásy, José Albino da Paz, Olga Ciccarelli, Ming Lim, Albert Saiz, Rinze Neuteboom, Romain Marignier, Cheryl Hemingway, Douglas Kazutoshi Sato, and Kumaran Deiva. Treatment and outcome of aquaporin-4 antibody–positive nmosd. Neurology Neuroimmunology & Neuroinflammation, Sep 2020. URL: https://doi.org/10.1212/nxi.0000000000000837, doi:10.1212/nxi.0000000000000837. This article has 72 citations.

31. (tugizova2021newtherapeuticlandscape pages 1-4): Madina Tugizova, Luka Vlahovic, Anna Tomczak, Nora Sandrine Wetzel, and May Htwe Han. New therapeutic landscape in neuromyelitis optica. Current Treatment Options in Neurology, Mar 2021. URL: https://doi.org/10.1007/s11940-021-00667-3, doi:10.1007/s11940-021-00667-3. This article has 28 citations and is from a peer-reviewed journal.

32. (contentti2021neuromyelitisopticaspectrum pages 11-13): Edgar Carnero Contentti and Jorge Correale. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. Journal of Neuroinflammation, Sep 2021. URL: https://doi.org/10.1186/s12974-021-02249-1, doi:10.1186/s12974-021-02249-1. This article has 376 citations and is from a peer-reviewed journal.

33. (traboulsee2020safetyandefficacy pages 1-2): Anthony Traboulsee, Benjamin M Greenberg, Jeffrey L Bennett, Lech Szczechowski, Edward Fox, Svitlana Shkrobot, Takashi Yamamura, Yusuke Terada, Yuichi Kawata, Padraig Wright, Athos Gianella-Borradori, Hideki Garren, and Brian G Weinshenker. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. The Lancet Neurology, 19:402-412, May 2020. URL: https://doi.org/10.1016/s1474-4422(20)30078-8, doi:10.1016/s1474-4422(20)30078-8. This article has 585 citations and is from a highest quality peer-reviewed journal.

34. (tugizova2021newtherapeuticlandscape pages 9-11): Madina Tugizova, Luka Vlahovic, Anna Tomczak, Nora Sandrine Wetzel, and May Htwe Han. New therapeutic landscape in neuromyelitis optica. Current Treatment Options in Neurology, Mar 2021. URL: https://doi.org/10.1007/s11940-021-00667-3, doi:10.1007/s11940-021-00667-3. This article has 28 citations and is from a peer-reviewed journal.

35. (chan2021treatmentofneuromyelitis pages 17-19): Koon-Ho Chan and Chi-Yan Lee. Treatment of neuromyelitis optica spectrum disorders. International Journal of Molecular Sciences, 22:8638, Aug 2021. URL: https://doi.org/10.3390/ijms22168638, doi:10.3390/ijms22168638. This article has 74 citations.

36. (xu2025aquaporin4iggseropositiveneuromyelitisoptica pages 4-5): Li Xu, Huiming Xu, and Changyong Tang. Aquaporin-4-igg-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis. Neural Regeneration Research, 20:354-365, Jan 2024. URL: https://doi.org/10.4103/nrr.nrr-d-23-01325, doi:10.4103/nrr.nrr-d-23-01325. This article has 16 citations and is from a peer-reviewed journal.

37. (xu2025aquaporin4iggseropositiveneuromyelitisoptica pages 8-8): Li Xu, Huiming Xu, and Changyong Tang. Aquaporin-4-igg-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis. Neural Regeneration Research, 20:354-365, Jan 2024. URL: https://doi.org/10.4103/nrr.nrr-d-23-01325, doi:10.4103/nrr.nrr-d-23-01325. This article has 16 citations and is from a peer-reviewed journal.

38. (namatame2024humanizedaquaporin4expressingratcreated pages 1-2): Chihiro Namatame, Yoichiro Abe, Yoshiki Miyasaka, Yoshiki Takai, Yuki Matsumoto, Toshiyuki Takahashi, Tomoji Mashimo, Tatsuro Misu, Kazuo Fujihara, Masato Yasui, and Masashi Aoki. Humanized-aquaporin-4-expressing rat created by gene-editing technology and its use to clarify the pathology of neuromyelitis optica spectrum disorder. International Journal of Molecular Sciences, 25:8169, Jul 2024. URL: https://doi.org/10.3390/ijms25158169, doi:10.3390/ijms25158169. This article has 4 citations.

39. (levy2021newtherapiesfor pages 3-4): Michael Levy, Kazuo Fujihara, and Jacqueline Palace. New therapies for neuromyelitis optica spectrum disorder. The Lancet Neurology, 20:60-67, Jan 2021. URL: https://doi.org/10.1016/s1474-4422(20)30392-6, doi:10.1016/s1474-4422(20)30392-6. This article has 170 citations and is from a highest quality peer-reviewed journal.